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Glycyrrhizin (GL) was reported as the most active in inhibiting replication of the severe acute respiratory 
syndrome (SARS)-associated coronavirus. Therapeutic effect of GL for liver dysfunction associated with 
cytomegalovirus (CMV) infection in immunocompetent individuals was evaluated. Liver dysfunction in 4 
cases improved and CMV disappeared from urinary samples after administration of GL intravenously by 
the age of 12 months. GL treatment also should be applied for the patients with SARS.  
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It was reported that glycyrrhizin (GL) is the most active in 
inhibiting replication of the SARS-associated coronavirus 
and GL should be assessed for treatment (Cinatl et al., 
2003). Some antiviral agents that express activity against 
virus-specific metabolic processes without displaying 
cytotoxicity have become available. Unfortunately, until 
present time, no successful treatment of SARS has yet 
been completely developed. GL, a Chinese herbal drug 
extracted from licorice roots, has shown to express 
antiviral effects and immunomodulating activities. 
Cell-free infection of HIV-1 and HIV-2 is almost 
completely blocked in the presence of GL.  Cell-to-cell 
infection by HIV-1, HIV-2, and human T-cell lymphotropic 
virus type I is also inhibited by GL. 
Although the exact mechanism of antiviral effects of GL 
is unclear, some therapeutic and prophylactic effects of 
GL on chronic active viral hepatitis have been claimed in 
Japan. It has been reported that suppressor T cells or 
macrophages generated by stimulation with allogenic 
lymphocytes were inhibited by intravenous administration 
of GL (Miyaji et al., 2002). It is likely that expression of 
viral genome on T lymphocytes as well as activities of 
some cytokines are associated with active viral infection. 
GL has been demonstrated to exhibit interferon-inducing 
and NK-enhancing activities. 
Human cytomegalovirus (CMV) is the most common 
cause of congenital and perinatal infections throughout 
the world.  We had evaluated anti-CMV properties GL 
both in vivo and in vitro (Numazaki and Chiba, 1993; 
Numazaki et al., 1994; Numazaki, 1998). Clinical 
symptoms and laboratory abnormal findings improved and 
CMV disappeared sooner from clinical specimens after 
intravenous administration of GL than in control. 
In previous study, therapeutic effect of GL for liver 
dysfunction associated with CMV infection in 
immunocompetent individuals was evaluated (Numazaki, 
1998). I administered 0.2% GL dissolved in saline (2 
mg/ml GL), supplemented with 2% glycine and 0.1% 
cysteine (Stronger Neo-Minophagen C, SNMC) 
intravenously to 4 infants (GL was administered 10-20 mg 
/kg/day intravenously for 8 weeks). I also administrated 
Glycyron (25 mg GL supplemented with 25 mg 
methionine and 25 mg glycine) orally to another 6 infants 





Liver dysfunction in 4 cases improved and CMV 
disappeared from urinary samples after administration of 
GL intravenously by the age of 12 months. In 6 infants 
liver dysfunction normalized and CMV disappeared by 
the age of 16 months after administration of GL orally. 
CMV disappeared from urine sooner after intravenous 
administration of GL than in controls (p<0.05). No side 
effects were noted during the treatment with GL. GL 
therapy was considered to be a suitable treatment for 
improving liver dysfunction in immunocompetent infants 
and children associated with CMV infection.   
GL treatment also should be applied for the patients 
with SARS. At first, GL treatment for SARS should be 
restricted for a short time. Unusual side effects such as 
hypertension and hypokalaemia were reported in some 
patients after several months of GL treatment. However, 
taken along with infrequent and very mild side effects, 
long-term intermittent GL treatment also would benefit 
patients with chronic phase of SARS by maintaining their 
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